PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Present at Jefferies Virtual Healthcare Conference
DURHAM, N.C. , May 28, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview and
View HTML
Toggle Summary Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update
DSTAT Explored as a Potential Novel Treatment for the Current Pandemic While an NDA is Being Prepared for Brincidofovir to Address a Potential Future Pandemic  DURHAM, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development
View HTML
Toggle Summary Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study Mechanisms of Action May Address Overactive Inflammatory Response, Including Underlying Causes of Blood Coagulation Disorders Associated with COVID-19 Company to Host Conference Call Today at 8:30 a.m.
View HTML
Toggle Summary Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
DURHAM, N.C. , April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S.
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 40th Annual Health Care Conference
DURHAM, N.C. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview at the
View HTML
Toggle Summary Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update
- Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML - - Brincidofovir pre-NDA Meeting Scheduled with FDA, on Track for mid-2020 NDA Filing - – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb.
View HTML
Toggle Summary Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
DURHAM, N.C. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Pratik S. Multani , M.D., to its Board of Directors, effective
View HTML
Toggle Summary Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020
DURHAM, N.C. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25,
View HTML
Toggle Summary Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting
Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection DURHAM, N.C. , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of
View HTML
Toggle Summary Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting
DURHAM, N.C. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known
View HTML